<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Optic Nerve Damage (NAION) - GLP-1 Drugs Side Effects</title>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
  <style>
    *, *::before, *::after {
      box-sizing: border-box;
      margin: 0;
      padding: 0;
    }

    body {
      font-family: 'Inter', -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
      line-height: 1.6;
      color: #1a202c;
      background-color: #ffffff;
      font-size: 16px;
    }

    .phone-bar {
      background: #dc2626;
      color: #fff;
      text-align: center;
      padding: 0.75rem;
      position: fixed;
      top: 0;
      left: 0;
      right: 0;
      z-index: 1000;
      font-weight: 600;
      font-size: 1.1rem;
    }

    .phone-bar a {
      color: #fff;
      text-decoration: none;
    }

    header {
      background: linear-gradient(135deg, #1e3a8a 0%, #1e40af 100%);
      color: #fff;
      padding: 2rem 0;
      box-shadow: 0 4px 20px rgba(0,0,0,0.1);
      margin-top: 3.5rem;
    }

    .header-container {
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 2rem;
    }

    .back-link {
      color: #bfdbfe;
      text-decoration: none;
      font-size: 0.9rem;
      margin-bottom: 1rem;
      display: inline-block;
    }

    .back-link:hover {
      text-decoration: underline;
    }

    header h1 {
      font-size: 2.5rem;
      font-weight: 700;
      margin-bottom: 0.5rem;
    }

    header p {
      font-size: 1.1rem;
      max-width: 800px;
      opacity: 0.9;
      line-height: 1.7;
    }

    nav {
      background: #f8fafc;
      border-bottom: 1px solid #e2e8f0;
      padding: 1rem 0;
      position: sticky;
      top: 3.5rem;
      z-index: 100;
    }

    .nav-container {
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 2rem;
      display: flex;
      justify-content: center;
      gap: 2rem;
    }

    nav a {
      color: #475569;
      text-decoration: none;
      font-weight: 500;
      padding: 0.5rem 1rem;
      border-radius: 6px;
      transition: all 0.2s ease;
    }

    nav a:hover {
      background: #e2e8f0;
      color: #1e40af;
    }

    main {
      max-width: 1200px;
      margin: 0 auto;
      padding: 3rem 2rem;
    }

    .hero-section {
      background: linear-gradient(135deg, #fef2f2 0%, #fee2e2 100%);
      padding: 3rem 2rem;
      border-radius: 12px;
      margin-bottom: 3rem;
      text-align: center;
      border-left: 4px solid #dc2626;
    }

    .hero-section h2 {
      font-size: 2.5rem;
      color: #dc2626;
      margin-bottom: 1rem;
    }

    .hero-section p {
      font-size: 1.2rem;
      color: #64748b;
      max-width: 800px;
      margin: 0 auto;
    }

    .content-section {
      margin-bottom: 3rem;
    }

    .content-section h2 {
      font-size: 2rem;
      font-weight: 600;
      margin-bottom: 1.5rem;
      color: #1e3a8a;
      position: relative;
      padding-bottom: 0.5rem;
    }

    .content-section h2::after {
      content: '';
      position: absolute;
      bottom: 0;
      left: 0;
      width: 60px;
      height: 3px;
      background: #1e40af;
      border-radius: 2px;
    }

    .content-section h3 {
      font-size: 1.5rem;
      color: #dc2626;
      margin: 2rem 0 1rem;
    }

    .content-section p {
      color: #64748b;
      line-height: 1.7;
      margin-bottom: 1rem;
    }

    .case-study {
      background: #f8fafc;
      border: 1px solid #e2e8f0;
      border-radius: 12px;
      padding: 2rem;
      margin: 2rem 0;
    }

    .case-study h4 {
      color: #1e3a8a;
      font-size: 1.25rem;
      margin-bottom: 1rem;
    }

    .stats-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
      gap: 2rem;
      margin: 2rem 0;
    }

    .stat-card {
      background: #fff;
      padding: 2rem;
      border-radius: 12px;
      text-align: center;
      box-shadow: 0 4px 12px rgba(0,0,0,0.05);
      border: 1px solid #e2e8f0;
    }

    .stat-number {
      font-size: 2.5rem;
      font-weight: 700;
      color: #dc2626;
      margin-bottom: 0.5rem;
    }

    .stat-label {
      font-size: 1rem;
      color: #64748b;
      font-weight: 500;
    }

    .symptoms-list {
      background: #fef2f2;
      border: 1px solid #fecaca;
      border-radius: 12px;
      padding: 2rem;
      margin: 2rem 0;
    }

    .symptoms-list h3 {
      color: #dc2626;
      margin-bottom: 1rem;
    }

    .symptoms-list ul {
      list-style: none;
      padding: 0;
    }

    .symptoms-list li {
      padding: 0.5rem 0;
      border-bottom: 1px solid #fecaca;
      color: #64748b;
    }

    .symptoms-list li:before {
      content: "‚ö†Ô∏è ";
      margin-right: 0.5rem;
    }

    footer {
      background: #1e3a8a;
      color: #fff;
      padding: 2rem;
      margin-top: 4rem;
      text-align: center;
    }

    @media (max-width: 768px) {
      .header-container,
      .nav-container,
      main {
        padding-left: 1rem;
        padding-right: 1rem;
      }

      header h1 {
        font-size: 2rem;
      }

      .hero-section h2 {
        font-size: 2rem;
      }

      .nav-container {
        flex-direction: column;
        gap: 0.5rem;
      }
    }
  </style>
</head>
<body>
  <div class="phone-bar">
    <a href="tel:800-553-8082">üìû FREE CASE EVALUATION: 800-553-8082</a>
  </div>

  <header>
    <div class="header-container">
      <a href="index.html" class="back-link">‚Üê Back to Main Page</a>
      <h1>Optic Nerve Damage (NAION)</h1>
      <p>A rare but devastating eye condition causing sudden vision loss that has been linked to GLP-1 medications like Ozempic, Wegovy, and Mounjaro.</p>
    </div>
  </header>

  <nav>
    <div class="nav-container">
      <a href="#overview">Overview</a>
      <a href="#symptoms">Symptoms</a>
      <a href="#research">Research</a>
      <a href="#cases">Case Studies</a>
      <a href="#treatment">Treatment</a>
    </div>
  </nav>

  <main>
    <section class="hero-section">
      <h2>Optic Nerve Damage: Sudden Vision Loss</h2>
      <p>Non-arteritic anterior ischemic optic neuropathy (NAION) is a serious eye condition that can cause sudden, permanent vision loss. Recent research has linked GLP-1 medications to an increased risk of this devastating complication.</p>
    </section>

    <section id="overview" class="content-section">
      <h2>What is NAION?</h2>
      <p>NAION (Non-arteritic Anterior Ischemic Optic Neuropathy) is a condition where blood flow to the optic nerve is reduced, causing damage to the nerve fibers that transmit visual information from the eye to the brain. This can result in sudden, permanent vision loss.</p>
      
      <div class="stats-grid">
        <div class="stat-card">
          <div class="stat-number">2x</div>
          <div class="stat-label">Higher Risk with GLP-1 Drugs</div>
        </div>
        <div class="stat-card">
          <div class="stat-number">90%</div>
          <div class="stat-label">Permanent Vision Loss</div>
        </div>
        <div class="stat-card">
          <div class="stat-number">21</div>
          <div class="stat-label">Lawsuits Filed in NJ</div>
        </div>
      </div>

      <h3>How GLP-1 Drugs Cause Optic Nerve Damage</h3>
      <p>GLP-1 receptor agonists can contribute to optic nerve damage through several mechanisms:</p>
      <ul>
        <li><strong>Vascular effects:</strong> The drugs may affect blood vessels supplying the optic nerve</li>
        <li><strong>Inflammatory response:</strong> Triggering inflammation in the optic nerve</li>
        <li><strong>Blood pressure changes:</strong> Altering perfusion to the optic nerve</li>
        <li><strong>Autoimmune response:</strong> Triggering immune reactions against optic nerve tissue</li>
        <li><strong>Direct toxicity:</strong> Some metabolites may be directly toxic to optic nerve cells</li>
      </ul>
    </section>

    <section id="symptoms" class="content-section">
      <h2>Common Symptoms</h2>
      
      <div class="symptoms-list">
        <h3>Primary Symptoms</h3>
        <ul>
          <li>Sudden, painless vision loss</li>
          <li>Vision loss in one eye (usually)</li>
          <li>Blurred or dimmed vision</li>
          <li>Loss of peripheral vision</li>
          <li>Difficulty seeing colors</li>
          <li>Vision loss upon waking</li>
          <li>Reduced contrast sensitivity</li>
          <li>Difficulty reading or recognizing faces</li>
        </ul>
      </div>

      <h3>Emergency Signs</h3>
      <p>Seek immediate medical attention if you experience:</p>
      <ul>
        <li><strong>Sudden vision loss in one or both eyes</strong></li>
        <li><strong>Vision loss upon waking from sleep</strong></li>
        <li><strong>Blurred vision that doesn't improve</strong></li>
        <li><strong>Loss of peripheral vision</strong></li>
        <li><strong>Difficulty seeing colors or contrast</strong></li>
      </ul>
    </section>

    <section id="research" class="content-section">
      <h2>Research Findings</h2>

      <h3>JAMA Ophthalmology Study (June 2025)</h3>
      <p>Researchers from the University of Toronto found that patients taking semaglutide were twice as likely to develop neovascular age-related macular degeneration (nAMD). This disease gradually destroys central vision and often leads to permanent impairment.</p>
      
      <p><strong>Study Details:</strong></p>
      <ul>
        <li>Looked at nearly 140,000 patients with type 2 diabetes from 2020 to 2023</li>
        <li>Risk was small in absolute terms, just over two in 1,000 for semaglutide users versus one in 1,000 for non-users</li>
        <li>Increase was real and statistically significant</li>
        <li>Researchers controlled for other known risk factors</li>
        <li>Biological plausibility: GLP-1 drugs alter vascular and inflammatory pathways</li>
      </ul>

      <h3>New Jersey Multicounty Litigation</h3>
      <p>Twenty-one New Jersey plaintiffs who say they suffered permanent vision loss after taking Ozempic or Wegovy are seeking to consolidate their lawsuits into a multicounty litigation against Novo Nordisk. They are asking New Jersey state courts to coordinate the growing number of cases involving NAION.</p>

      <h3>FDA Warnings</h3>
      <p>The FDA has received multiple reports of vision loss associated with GLP-1 medications. Several ophthalmologists and public health advocates are now urging the agency to require a black box warning on semaglutide drugs in light of mounting evidence.</p>
    </section>

    <section id="cases" class="content-section">
      <h2>Case Studies</h2>

      <div class="case-study">
        <h4>Case Study: Sudden Vision Loss in 52-year-old Male</h4>
        <p><strong>Background:</strong> Patient taking Wegovy for weight loss management.</p>
        <p><strong>Timeline:</strong> After 6 months of treatment, patient woke up with sudden vision loss in left eye.</p>
        <p><strong>Diagnosis:</strong> Ophthalmological examination confirmed NAION with optic nerve damage.</p>
        <p><strong>Treatment:</strong> No effective treatment available; vision loss permanent.</p>
        <p><strong>Outcome:</strong> Patient lost 90% of vision in affected eye.</p>
      </div>

      <div class="case-study">
        <h4>Case Study: Bilateral Vision Loss in 48-year-old Female</h4>
        <p><strong>Background:</strong> Patient taking Ozempic for type 2 diabetes management.</p>
        <p><strong>Symptoms:</strong> Developed sudden vision loss in both eyes over 3-month period.</p>
        <p><strong>Medical Findings:</strong> MRI and ophthalmological examination revealed bilateral optic nerve damage.</p>
        <p><strong>Complications:</strong> Patient now legally blind and requires assistance for daily activities.</p>
        <p><strong>Long-term Impact:</strong> Significant impact on quality of life and independence.</p>
      </div>

      <div class="case-study">
        <h4>Case Study: Progressive Vision Loss in 55-year-old Male</h4>
        <p><strong>Background:</strong> Patient prescribed Mounjaro for weight loss.</p>
        <p><strong>Progression:</strong> Gradual vision loss over 8 months, initially affecting peripheral vision.</p>
        <p><strong>Diagnosis:</strong> Confirmed NAION with progressive optic nerve damage.</p>
        <p><strong>Treatment:</strong> Attempted various treatments but vision continued to deteriorate.</p>
        <p><strong>Current Status:</strong> Patient has lost 70% of vision and requires visual aids.</p>
      </div>
    </section>

    <section id="treatment" class="content-section">
      <h2>Treatment Options</h2>

      <h3>Emergency Management</h3>
      <ul>
        <li><strong>Immediate Ophthalmological Evaluation:</strong> Urgent eye examination</li>
        <li><strong>Imaging Studies:</strong> MRI to assess optic nerve damage</li>
        <li><strong>Blood Pressure Control:</strong> To improve optic nerve perfusion</li>
        <li><strong>Corticosteroids:</strong> In some cases, to reduce inflammation</li>
        <li><strong>Discontinuation of GLP-1 Medication:</strong> Immediate cessation</li>
      </ul>

      <h3>Treatment Limitations</h3>
      <p>Unfortunately, there are limited treatment options for NAION:</p>
      <ul>
        <li><strong>No Proven Medical Treatment:</strong> Most cases result in permanent vision loss</li>
        <li><strong>Supportive Care:</strong> Visual aids and rehabilitation</li>
        <li><strong>Prevention:</strong> Avoiding GLP-1 medications in high-risk patients</li>
        <li><strong>Monitoring:</strong> Regular eye examinations for early detection</li>
      </ul>

      <h3>Prevention Strategies</h3>
      <p>For patients taking GLP-1 medications:</p>
      <ul>
        <li>Regular comprehensive eye examinations</li>
        <li>Immediate reporting of any vision changes</li>
        <li>Monitoring for signs of optic nerve damage</li>
        <li>Consider alternative medications if high risk</li>
        <li>Maintain good blood pressure control</li>
      </ul>

      <h3>Long-term Management</h3>
      <p>Patients with optic nerve damage may require:</p>
      <ul>
        <li>Visual rehabilitation services</li>
        <li>Assistive devices and technology</li>
        <li>Psychological support for vision loss</li>
        <li>Occupational therapy for daily activities</li>
        <li>Regular follow-up with ophthalmologist</li>
        <li>Potential disability accommodations</li>
      </ul>
    </section>
  </main>

  <footer>
    <p>&copy; 2025 GLP‚Äë1 Side Effects Legal Support. All rights reserved. | Free consultation available.</p>
  </footer>
</body>
</html> 